OpenAI has invested in Merge Labs, a brain-computer interface firm co-founded by its CEO Sam Altman.
This was part of a $252 million seed funding at a valuation of $850 million.
The funding, with OpenAI being the biggest donor, gives Merge Labs a competitive position in developing non-invasive neural technologies.
How Merge Labs Advances Human-AI Ties
Merge Labs is a research lab that focuses on the intersection of biology and AI.
They are developing a safe and high-speed brain-computer interface. The company aims to achieve seamless human-AI interaction.
This will result in the enhancement of human abilities beyond the use of implants.
Although it has rivals such as Neuralink, Merge Labs’ use of either ultrasound or molecular techniques, instead of the surgery-required electrodes of its rivals, may make it simpler for it to clear regulatory hurdles and be widely accepted.
OpenAI’s role will go further than an investment. This will include collaboration with the AI company on scientific models for accelerating BCI development.
This focuses on their pursuit for natural human-AI interaction.
It has several impacts on those involved in developing AI technology and those involved in controlling it.
It is an indication of the future focus being on augmentation and not automation in various sectors such as the healthcare and education sectors.
Timeline of Merge Labs Launch
Merge Labs emerged from stealth on 15 January 2026, after being founded in 2024 as a spinout of nonprofit Forest Neurotech.
Among the co-founders are researchers Mikhail Shapiro, Tyson Aflalo, and Sumner Norman, plus entrepreneurs Alex Blania, Sandro Herbig, and Sam Altman in a personal capacity.
The $252 million round is led by Bain Capital, joined by Gabe Newell among others, and comes after reports of fundraising talks in 2025.
The initial focus of the company is engineering team expansion and the initiation of clinical trials by late 2026.
Funds Target Trials and Security
With capital infusion, Merge Labs will be able to increase its workforce, accelerate its research in neural decoding, and start early clinical trials.
Funding for privacy frameworks is intended to ensure the security of neural data.
OpenAI believes that the collaboration is essential for integrating advanced AI systems with human brain functions.
This industry faces stringent regulation regarding trials and privacy. Merge Lab’s non-invasive approach might prove beneficial in these situations.
It is, however, necessary to develop public trust.
There are counterpoints to this issue: There could be conflicts of interest involved, given that Altman has two roles.
Next Steps for Merge Labs
Merge Labs to start their first clinical trials in Q4 of 2026, while their FDA submissions are expected in mid-2027.
OpenAI and Merge will publish collaborative research updates in H2 2026.
Some of the key milestones include the testing of prototypes by December 2026 and the establishment of partnerships with medical institutions.
